Session 15: Special Topics in HR+ Breast Cancer Time Zone: ET
Presenter: Kevin Kalinsky, MD, MS – Winship Cancer Institute at Emory University
Kevin Kalinsky, MD, MS (he/him/his) – Winship Cancer Institute at Emory University ### 1538154###Presenter###Director, Glenn Family Breast Center###Winship Cancer Institute at Emory University###
Presenter: Kevin Kalinsky, MD, MS (he/him/his) – Winship Cancer Institute at Emory University
### he/him/his
8:50 AM – 9:00 AM ET
Live Q&A
8:50 AM – 9:00 AM ET
Live Q&A Time Zone: ET
Moderator: Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI)
Presenter: Kevin Kalinsky, MD, MS – Winship Cancer Institute at Emory University
Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI) ### 1186741###Moderator###Director, Breast and Gynecologic Cancer Research Program###Sarah Cannon Research Institute (SCRI)###
Moderator: Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI)
### @@@ Kevin Kalinsky, MD, MS (he/him/his) – Winship Cancer Institute at Emory University ### 1538154###Presenter###Director, Glenn Family Breast Center###Winship Cancer Institute at Emory University###
Presenter: Kevin Kalinsky, MD, MS (he/him/his) – Winship Cancer Institute at Emory University
Session 16: ER-Positive Targeted Therapy: PI3, AKT, mTOR, etc Time Zone: ET
Presenter: Joyce O'Shaughnessy, MD – Baylor Charles A. Sammons Cancer Center/ Baylor University Medical Center/ Texas Oncology
Joyce O'Shaughnessy, MD – Baylor Charles A. Sammons Cancer Center/ Baylor University Medical Center/ Texas Oncology ### 1879169###Presenter###Medical Oncologist###Baylor Charles A. Sammons Cancer Center/ Baylor University Medical Center/ Texas Oncology###
Presenter: Joyce O'Shaughnessy, MD – Baylor Charles A. Sammons Cancer Center/ Baylor University Medical Center/ Texas Oncology
###
10:00 AM – 10:15 AM ET
Break
10:00 AM – 10:15 AM ET
Break Time Zone: ET
10:15 AM – 11:15 AM ET
Non-CME Innovation Theater
10:15 AM – 11:15 AM ET
Non-CME Innovation Theater Time Zone: ET
11:15 AM – 11:30 AM ET
Break
11:15 AM – 11:30 AM ET
Break Time Zone: ET
11:30 AM – 12:05 PM ET
Session 17: HER2-Positive Metastatic Breast Cancer: Where are We Headed?
11:30 AM – 12:05 PM ET
Session 17: HER2-Positive Metastatic Breast Cancer: Where are We Headed? Time Zone: ET
Presenter: Sara Hurvitz, MD – University of California, Los Angeles
Sara Hurvitz, MD – University of California, Los Angeles ### 1186881###Presenter###Professor of Medicine###University of California, Los Angeles###
Presenter: Sara Hurvitz, MD – University of California, Los Angeles
###
11:30 AM – 12:15 PM ET
Session 17: HER2-Positive Metastatic Breast Cancer: Where are We Headed?
12:05 PM – 12:15 PM ET
Live Q&A Time Zone: ET
Moderator: Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI)
Presenter: Sara Hurvitz, MD – University of California, Los Angeles
Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI) ### 1186741###Moderator###Director, Breast and Gynecologic Cancer Research Program###Sarah Cannon Research Institute (SCRI)###
Moderator: Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI)
### @@@ Sara Hurvitz, MD – University of California, Los Angeles ### 1186881###Presenter###Professor of Medicine###University of California, Los Angeles###
Presenter: Sara Hurvitz, MD – University of California, Los Angeles
###
12:15 PM – 12:30 PM ET
Break
12:15 PM – 12:30 PM ET
Break Time Zone: ET
12:30 PM – 1:05 PM ET
Session 18: Immunotherapy for Breast Cancer
12:30 PM – 1:05 PM ET
Session 18: Immunotherapy for Breast Cancer Time Zone: ET
Presenter: Javier Cortes, MD, PhD – International Breast Cancer Center , IBCC
Javier Cortes, MD, PhD – International Breast Cancer Center , IBCC ### 1186877###Presenter###Head###International Breast Cancer Center , IBCC###
Presenter: Javier Cortes, MD, PhD – International Breast Cancer Center , IBCC
###
1:05 PM – 1:15 PM ET
Live Q&A
1:05 PM – 1:15 PM ET
Live Q&A Time Zone: ET
Moderator: Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI)
Presenter: Javier Cortes, MD, PhD – International Breast Cancer Center , IBCC
Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI) ### 1186741###Moderator###Director, Breast and Gynecologic Cancer Research Program###Sarah Cannon Research Institute (SCRI)###
Moderator: Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI)
### @@@ Javier Cortes, MD, PhD – International Breast Cancer Center , IBCC ### 1186877###Presenter###Head###International Breast Cancer Center , IBCC###
Presenter: Javier Cortes, MD, PhD – International Breast Cancer Center , IBCC
###
1:15 PM – 1:30 PM ET
Break
1:15 PM – 1:30 PM ET
Break Time Zone: ET
1:30 PM – 2:05 PM ET
Session 19: ADCs: A New Technology
1:30 PM – 2:05 PM ET
Session 19: ADCs: A New Technology Time Zone: ET
Presenter: Giuseppe Curigliano, Professor MD PhD – European Insitute of Oncology, IRCCS and University of Milano
Giuseppe Curigliano, Professor MD PhD (he/him/his) – European Insitute of Oncology, IRCCS and University of Milano ### 1867030###Presenter###Clinical Director Early Drug Development Division###European Insitute of Oncology, IRCCS and University of Milano###
Presenter: Giuseppe Curigliano, Professor MD PhD (he/him/his) – European Insitute of Oncology, IRCCS and University of Milano
### he/him/his
2:05 PM – 2:15 PM ET
Live Q&A
2:05 PM – 2:15 PM ET
Live Q&A Time Zone: ET
Moderator: Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI)
Presenter: Giuseppe Curigliano, Professor MD PhD – European Insitute of Oncology, IRCCS and University of Milano
Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI) ### 1186741###Moderator###Director, Breast and Gynecologic Cancer Research Program###Sarah Cannon Research Institute (SCRI)###
Moderator: Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI)
### @@@ Giuseppe Curigliano, Professor MD PhD (he/him/his) – European Insitute of Oncology, IRCCS and University of Milano ### 1867030###Presenter###Clinical Director Early Drug Development Division###European Insitute of Oncology, IRCCS and University of Milano###
Presenter: Giuseppe Curigliano, Professor MD PhD (he/him/his) – European Insitute of Oncology, IRCCS and University of Milano
### he/him/his
2:15 PM – 2:30 PM ET
Break
2:15 PM – 2:30 PM ET
Break Time Zone: ET
2:30 PM – 3:15 PM ET
Session 20: Novel Endocrine Backbones
2:30 PM – 3:15 PM ET
Session 20: Novel Endocrine Backbones Time Zone: ET
Presenter: Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI)
Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI) ### 1186741###Presenter###Director, Breast and Gynecologic Cancer Research Program###Sarah Cannon Research Institute (SCRI)###
Presenter: Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI)
###
3:15 PM – 3:30 PM ET
Break
3:15 PM – 3:30 PM ET
Break Time Zone: ET
3:30 PM – 4:05 PM ET
Session 21: HER2-Low Breast Cancer: Limits of Testing and Where To Go From Here
3:30 PM – 4:05 PM ET
Session 21: HER2-Low Breast Cancer: Limits of Testing and Where To Go From Here Time Zone: ET
Presenter: Paolo Tarantino, MD – Dana-Farber Cancer Institute, Harvard Medical School
Paolo Tarantino, MD (he/him/his) – Dana-Farber Cancer Institute, Harvard Medical School ### 1928334###Presenter###Advanced Research Fellow###Dana-Farber Cancer Institute, Harvard Medical School###
Presenter: Paolo Tarantino, MD (he/him/his) – Dana-Farber Cancer Institute, Harvard Medical School
### he/him/his
4:05 PM – 4:15 PM ET
Live Q&A
4:05 PM – 4:15 PM ET
Live Q&A Time Zone: ET
Moderator: Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI)
Presenter: Paolo Tarantino, MD – Dana-Farber Cancer Institute, Harvard Medical School
Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI) ### 1186741###Moderator###Director, Breast and Gynecologic Cancer Research Program###Sarah Cannon Research Institute (SCRI)###
Moderator: Erika P. Hamilton, MD – Sarah Cannon Research Institute (SCRI)
### @@@ Paolo Tarantino, MD (he/him/his) – Dana-Farber Cancer Institute, Harvard Medical School ### 1928334###Presenter###Advanced Research Fellow###Dana-Farber Cancer Institute, Harvard Medical School###
Presenter: Paolo Tarantino, MD (he/him/his) – Dana-Farber Cancer Institute, Harvard Medical School
